TORONTO, April 19, 2018 /CNW/ - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("Xanthic" or the "Company") (CSE: xTHC) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange ("CSE") under the symbol "xTHC" effective at the market open on April 19, 2018.
Tim Moore, the CEO of Xanthic, commented, "Commencing trading on the CSE is a major corporate milestone for the Xanthic team. This significant accomplishment would not have been possible without the progress made by our management team, key advisors, consultants and Board in the past year. As we enter this next phase of our corporate development, our team is excited to continue to execute our strategic vision and to provide value to our current and future shareholders."
Further information regarding the Company is set forth in the Company's listing statement, a copy of which is available under the Company's SEDAR profile at www.sedar.com.
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility and consistency versus competitive infused products.
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). The use of any of the word "will" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.
SOURCE Xanthic BioPharma
For further information: Tim Moore, CEO, Xanthic Biopharma Inc., firstname.lastname@example.org, Phone: 1-647-966-6536, email@example.com